NCT04686045|Unknown
Loading search results
Sponsor study identifier
observational
10,000
1 country
2
Study Start
January 1, 2021
Actual (reported)Primary Completion
March 1, 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
May 1, 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Prevention of thromboembolic complications is an important part in the management of patients with atrial fibrillation (AF). European and American guidelines recommend the use of non-vitamin K antagonist oral anticoagulants (NOACs) over therapy with vitamin K antagonists (VKA) in most AF patients. The number of patients treated with NOACs has increased significantly during the last few years. In the primary randomized controlled trials leading to their approval, compared to warfarin, NOACs were shown to be either noninferior or superior for stroke prevention in AF, with similar or reduced rates of bleeding, especially intracranial haemorrhage. The aim of this study was to assess the frequency of oral anticoagulants using, espescially apixaban, dabigatran, and rivaroxaban, and the predictors of their prescription in a group of hospitalised patients with AF.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
May 1, 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
December 22, 2020
Actual (reported)December 28, 2020
Actual (reported)January 1, 2021
Actual (reported)March 1, 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
May 1, 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
oral anticoagulant treatment
one year
observational study
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
All patients with AF treated in hospital.
1st Clinic of Cardiology and Electotherapy
Kielce, Grunwaldzka 45, 25-637, Poland
Iwona Gorczyca
Kielce, 25-525, Poland
First Submitted
December 22, 2020
First Posted
December 28, 2020
Study Start
January 1, 2021
Actual (reported)Primary Completion
March 1, 2021
Estimated (date passed)Acute Pancreatitis and Thrombosis (PATHRO)
Contact the study team to confirm eligibility.
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
May 1, 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
January 26, 2021
Record last verified: 2021-01
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: